Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of anti-human csf-1r monoclonal antibody and its application

A CSF-1R and monoclonal antibody technology, applied in the direction of antibodies, anti-animal/human immunoglobulins, applications, etc., can solve problems that need further research and development, and achieve the effect of novel sequences

Active Publication Date: 2020-06-19
BIOSION INC
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Although CSF1R antibodies have been developed, CSF1R inhibitors with higher affinity and other key properties of drugs for the treatment of the above diseases, especially monoclonal antibodies, still need to be further researched and developed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of anti-human csf-1r monoclonal antibody and its application
  • A kind of anti-human csf-1r monoclonal antibody and its application
  • A kind of anti-human csf-1r monoclonal antibody and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Example 1 Obtaining specific anti-CSF1R mouse monoclonal antibody by fusion hybridoma technology

[0036] 1.1 Animal Immunization

[0037] Mice were immunized according to general methods in the literature (E Harlow, D. Lane, Antibody: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1998). The immunogen was a recombinant human CSF1R (amino acid Ile20-Glu 512) protein (Acrobiosystems, Cat#CSR-H5258) containing a human IgG1 Fc-tag at the C-terminus. Recombinant human CSF1R his-tagged protein (Acro biosystems, cat#CSR-H5228) was used as the detection antigen for serum titer determination and hybridoma screening. Briefly, remove an appropriate amount of Freund's adjuvant into a 1.5ml EP tube and mix well with a shaker. Prepare antigen protein solution with PBS. Mix the adjuvant and the protein antigen solution according to the required amount, push each other through a syringe to fully emulsify the antigen to form a stable water-in-oil...

Embodiment 2

[0043] Example 2 In Vitro Assay for Determining the Functional Activity of CSF1R Monoclonal Antibodies

[0044] 2.1 Determination of antibody binding capacity based on capture ELSIA

[0045] A goat anti-mouse IgG Fcr-specific secondary antibody (Jackson Immuno Research, #115-006-071) was prepared with 1xPBS to a final concentration of 2μg / ml, and 100μl / well was added to a 96-well microtiter plate at 4°C Wrap overnight. The next day, after washing the plate 4 times with PBS containing 0.05% Tween 20 (ie 1×PBST), 200 μl / well of 5% nonfat dry milk in PBST was added and placed at 37 degrees for blocking for 2 hours. Wash the plate again, add 100 μl / well of diluted antibody solution or hybridoma supernatant, incubate at 37°C for 40 minutes, and then wash the plate 4 times. The prepared 60nM biotin-labeled human CSF1R Fc protein solution (in 2.5% nonfat dry milk in PBST) was added at 100 μl / well, incubated at 37°C for 40 minutes, and then the plate was washed 4 times. Add 1:10000...

Embodiment 3

[0055] Example 3 Binding activity of anti-CSF1R mouse monoclonal antibody

[0056] According to the assay method described in Example 2, the binding activity of the CSF1R antibody was assessed and summarized in Table 2 below. Among them, Benchmark (Cabiralizumab) was used as a control, which is an existing uncommercialized anti-human CSF1R monoclonal antibody. It can be seen from Table 2 that the binding activity of the anti-human CSF-1R monoclonal antibody of the present invention to the human CSF1R antigen is significantly better than that of Benchmark.

[0057] Table 2 Binding activity of CSF1R antibodies

[0058]

[0059]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an anti-human CSF-1R monoclonal antibody and application thereof. Meanwhile, the invention provides a coding nucleic acid molecule of the antibody, an expression vector, a host cell and a method which is used for expressing the antibody. The invention further provides an antibody immunoconjugate, a bi-specific molecule, a chimeric antigen receptor, a medicine compound andapplication of the antibody. Compared with the prior art, the anti-human CSF-1R monoclonal antibody has the following advantages that the monoclonal antibody can specifically recognize human CSF-1R, the binding affinity of the antibody and the human CSF-1R is higher than those of existing anti-human CSF-1R monoclonal antibodies, sequences of the anti-human CSF-1R monoclonal antibody are novel, andthe anti-human CSF-1R monoclonal antibody bonds a unique epitope.

Description

technical field [0001] The present invention relates to a high-affinity and functional anti-human CSF1R monoclonal antibody or antibody fragment. The present invention also provides a nucleic acid molecule encoding the antibody, an expression vector, a host cell, and a method for expressing the antibody. Antibody immunoconjugates, bispecific molecules, chimeric antigen receptors, pharmaceutical compositions, and diagnostic and therapeutic methods comprising the antibodies of the invention are also provided. Background technique [0002] Colony stimulating factor 1 receptor (CSF-1R), belonging to the type III receptor tyrosine kinase family, encoded by the proto-oncogene c-fms, the protein structure contains an intracellular kinase domain and an extracellular by 5 immunoglobulins Ligand-binding domain composed of protein-like structures. CSF1R is expressed on the surface of mononuclear phagocytes and plays a key role in the survival, proliferation and differentiation of mon...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/28C12N15/13A61K39/395A61P35/00A61P19/02A61P29/00A61P9/10A61P19/00
CPCA61P9/10A61P19/00A61P19/02A61P29/00A61P35/00C07K16/2866C07K2317/56C07K2317/565C07K2317/76C07K2317/92
Inventor 陈明久谭巍
Owner BIOSION INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com